Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

The phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Belch, Andrew, Bahlis, Nizar, White, Darrell, Cheung, Matthew, Chen, Christine, Shustik, Chaim, Song, Kevin, Tosikyan, Axel, Dispenzieri, Angela, Anderson, Kenneth, Brown, Diane, Robinson, Suzanne, Srinivasan, Shankar, Facon, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724300/
https://www.ncbi.nlm.nih.gov/pubmed/33049118
http://dx.doi.org/10.1002/cam4.3511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724300/
https://www.ncbi.nlm.nih.gov/pubmed/33049118
http://dx.doi.org/10.1002/cam4.3511

Ejemplares similares